Evidence map›Paper›PMID 41584318›Full record

ReviewJournal of diabetes and metabolic disorders2026

Probiotics for managing non-alcoholic fatty liver disease: efficacy and mechanistic insights.

Supriyo Ghosh, Amlan Jyoti Ghosh, Manab Deb Adhikari, Bipransh Kumar Tiwary, Tilak Saha

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Supriyo GhoshImmunology and Microbiology Laboratory, Department of Zoology, University of North Bengal, Siliguri, West Bengal India.
Amlan Jyoti GhoshImmunology and Microbiology Laboratory, Department of Zoology, University of North Bengal, Siliguri, West Bengal India.
Manab Deb AdhikariDepartment of Biotechnology, University of North Bengal, Siliguri, West Bengal India.
Bipransh Kumar TiwaryDepartment of Microbiology, North Bengal St. Xavier's College, Rajganj, Jalpaiguri, West Bengal India.
Tilak SahaImmunology and Microbiology Laboratory, Department of Zoology, University of North Bengal, Siliguri, West Bengal India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a condition characterized by excess fat accumulation in the liver unrelated to alcohol consumption. Emerging scientific research suggests that probiotics supplementation is a useful therapeutic strategy for managing NAFLD without harmful side effects of conventional drugs. Several scientific studies suggest that, probiotics have the ability for enhancing production of beneficial microbial metabolites (e.g. SCFAs, indole), modulating gut microbiota composition, which in turn are connected to suppression of hepatic damage. Studies also suggest direct link of probiotics on modulation of liver enzymes, which are critical indicators of liver health. Probiotic strains such as

Indexed as

Anti-oxidantBile acidIntestinal permeabilityNAFLDProbioticsSCFA

Identifiers

PMID41584318
PMCPMC12830542

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.